Methylmalonic Acid Test: When a Normal B12 Is Not Normal

A B12 result inside the reference range is the most common way this deficiency stays hidden. A methylmalonic acid test exists because a serum B12 level answers a narrow question, how much of the vitamin is circulating on any carrier at all, and says nothing about whether your cells can use it. I walk through the absorption machinery in The Normal B12 That Wasn’t, the video for The Angry Gut, Chapter 6. Here the subject is measurement: which markers to order, what each one gets wrong, and what repair looks like once the number is finally read correctly.

Why one serum B12 cannot settle the question

Most of what a standard B12 assay counts is bound to haptocorrin, a carrier that does not hand the vitamin to cells. The fraction cells actually take up travels on transcobalamin and is called holotranscobalamin. A total level is a head count of every passenger on the highway, including the ones whose car never reaches an exit.

The cutoff is older than the machines. The familiar 200 ng/L line traces to a single study reporting 90% to 95% of deficient patients below 200, 5% to 10% between 200 and 300, and under 1% above 300. English guidance has since swapped the line for a band, calling 180 to 350 ng/L indeterminate. American primary care uses the same numbers in pg/mL: under 180 is diagnostic, and 180 to 350 is borderline and calls for methylmalonic acid.

Then the instrument changes the verdict. On one analyzer, reference ranges sit near 182 to 692 ng/L for Asian and White patients and near 225 to 1091 ng/L for Black patients. Another manufacturer’s platform runs close to 145 to 424 ng/L. One tube of blood can be low on one machine and unremarkable on the next.

In a diagnostic study of patients with megaloblastic anemia, using methylmalonic acid as the yardstick, total serum B12 identified 63% of the deficient, while holotranscobalamin identified 98.9%. Worse, the total level runs falsely reassuring in the very people most likely to be short: those carrying high-titer intrinsic factor antibodies, heterophile interference or excess haptocorrin.

What the methylmalonic acid test actually measures

Methylmalonic acid accumulates when B12 fails at its job inside the cell. That makes it a functional marker. It reports on the chemistry, not the inventory. Raised more than three standard deviations above the normal mean, it detects B12 deficiency with a sensitivity of 98.4%, and homocysteine, the other functional marker, reaches 95.9%.

These are the thresholds I work from. Methylmalonic acid above 280 nmol/L points to suboptimal status in younger adults with healthy kidneys, and above 750 nmol/L is accepted as definite. Holotranscobalamin under 25 pmol/L means deficiency; 25 to 70 is a gray zone that needs a second marker before anyone decides.

The marker is honest about B12 and gullible about almost everything else. Impaired kidney function raises it. So do dehydration, an underactive thyroid, small-bowel bacterial overgrowth producing propionic acid, inherited methylmalonic aciduria and a variant in the HIBCH gene. A high reading in a dehydrated patient with weak kidneys is a question, not an answer.

Two markers agree where one argues

A Swiss and German laboratory group ran four B12 markers on 3,614 routine samples. Holotranscobalamin was the best single test, with an area under the curve of 0.94. Paired with methylmalonic acid it rose to 0.98, and three-marker combinations reached 0.99. In a stepwise algorithm, a composite score lifted the positive likelihood ratio for deficiency from 12.1 to 42.6.

The reference standard there was an equation built from the markers themselves, so read it as agreement with a formula, not with disease. The direction still holds: a functional marker beside the level stops the level misleading on its own.

The first brain behind the number

A low functional B12 is a downstream reading. Upstream is the first brain: a stomach lining whose parietal cells make intrinsic factor, the protein that escorts the vitamin to the far end of the small bowel. Lose those cells and no blood value will announce it, because the Schilling test that once measured absorption directly no longer exists.

Two biological forces do most of the destroying. With Helicobacter pylori on board, new atrophic gastritis develops at 5.0 times the rate seen without it, while autoimmune attack on the parietal cells does the rest. The third force is economic. The calories we subsidize produce type 2 diabetes, the diabetes earns metformin, and in a randomized placebo-controlled trial metformin lowered serum B12 by 19% over 4.3 years. Acid-suppressing drugs taken for two years or more carry an odds ratio of 1.65 for deficiency, and Chapter 20, The Heartburn Pill You Can’t Quit, follows why so many of those prescriptions outlive their reason.

Here is the pattern a single B12 result cannot show. Iron usually goes first. In a stomach with corpus-predominant atrophy, iron deficiency turns up in as many as half of patients and often appears well before any B12 problem, because iron stores drain faster. In a prospective study of 270 patients, the lining advanced in every one, with none regressing. An old low ferritin buried in a chart may be the earliest trace of a failing stomach.

Antibodies earn their place only as a pair. Anti-intrinsic factor antibody has a specificity of 100% but a sensitivity of 38%, and it tends to turn positive late. Together the two reached a sensitivity of 90% and a specificity of 95.7%. And a proton pump inhibitor raises plasma gastrin three to five times, so a gastrin drawn on the drug reports on the pill rather than the stomach.

Repair starts once the reading is right

The test decides the route. Passive diffusion moves about 1% of an oral dose across the gut wall even without intrinsic factor, which is why high-dose tablets are not absurd. The largest trial, 283 patients in primary care, matched injections at eight weeks but fell short across the year: 73.6% normalized on tablets against 80.4% on injections. Only 10.8% of those patients carried intrinsic factor antibodies. The case for tablets is built mostly on stomachs that still work. Where the parietal cells are gone, this practice replaces the lost function by injection, for life.

The same trial holds a detail worth more than the route debate. Reaching a level above 281 pg/mL by week eight predicted success at one year with an odds ratio of 8.10, while the route itself did not, at 1.10. Load the stores, recheck early with a functional marker, and read the chemistry rather than the habit.

Terrain work runs alongside. Insulin resistance is the reason many people take metformin in the first place, and food, sleep and movement that lower insulin shrink the metabolic load the drug was prescribed to carry; any change to the prescription itself goes through your physician. Where H. pylori is present, eradication removes the driver, and although much of the damage may already be past a point of no return, eradication still appears to lower gastric cancer risk. For why a broken metabolism undermines every downstream fix, read why you cannot out-inject a broken metabolism.

The previous installment, Chapter 5, The Alcohol You Never Drank, and the next, Chapter 7 on what the gut wall is built from. For every study above with its full numbers and what each one does and does not show, open the Chapter 6 Deep Dive, the full evidence file with physician questions.

Frequently asked questions

What does a high methylmalonic acid level mean?

It usually means B12 is not working inside your cells, even if the blood level looks acceptable. Above 280 nmol/L suggests suboptimal status in younger adults with healthy kidneys, and above 750 nmol/L is accepted as definite deficiency. Kidney impairment, dehydration, thyroid problems and bacterial overgrowth can also raise it, so it has to be read against the rest of the chart. See how a full metabolic audit reads markers in context.

Can you be B12 deficient with a normal B12 level?

Yes. Most of the vitamin a standard assay counts rides on a carrier that never delivers it to cells. In patients with megaloblastic anemia, total serum B12 caught only 63% of deficient cases when methylmalonic acid was the reference. The level also reads falsely normal in people with high intrinsic factor antibodies. Read what low B12 does to the brain over years.

Is holotranscobalamin a better test than serum B12?

As a single marker, yes. It measures the fraction of B12 bound to transcobalamin, the form cells take up, and it identified 98.9% of deficient patients in a megaloblastic anemia study. Under 25 pmol/L means deficiency; 25 to 70 needs a second marker. Paired with methylmalonic acid, it discriminated better than either test alone. Learn why a clean result and real symptoms can coexist.

Is a very high B12 level a good sign?

Not automatically. A level persistently above 1,000 pg/mL on two measurements has been associated with solid tumors, blood cancers and a higher risk of cardiovascular death. A high number is something to explain with your physician, not a reason to stop looking, and it deserves the same functional follow-up as a low one. Explore how inflammaging changes what your body is telling you.

Sources

1. Harrington, D. J., Stevenson, E., & Sobczyńska-Malefora, A. (2024). The application and interpretation of laboratory biomarkers for the evaluation of vitamin B12 status. Annals of Clinical Biochemistry, 62(1), 22-33. https://doi.org/10.1177/00045632241292432
2. Tufail, N., Kataria, M., Chaudhary, A. J., Dhillon, R. A., Asif Naveed, M., & Mohsin, S. (2024). Comparing holotranscobalamin and total vitamin B12 in diagnosing vitamin B12 deficiency in megaloblastic anemia patients. Cureus, 16(10), e71278. https://doi.org/10.7759/cureus.71278
3. Campos, A. J., Risch, L., Nydegger, U., Wiesner, J., Dyck, M. V. V., Seger, C., Stanga, Z., Renz, H., & Risch, M. (2020). Diagnostic characteristics of 3-parameter and 2-parameter equations for the calculation of a combined indicator of vitamin B12 status to predict cobalamin deficiency in a large mixed patient population. Clinical Laboratory, 66(10). https://doi.org/10.7754/Clin.Lab.2020.200130
4. Patel, H., & McGuirk, R. (2025). Vitamin B12 deficiency: Common questions and answers. American Family Physician, 112(3), 294-300. https://pubmed.ncbi.nlm.nih.gov/40961307/
5. Osmola, M., Hémont, C., Romańczyk, M., Druet, A., Chapelle, N., Matysiak-Budnik, T., Lenti, M. V., & Martin, J. C. (2025). A comparative study of different assays for autoantibodies detection in patients with autoimmune gastritis. Journal of Translational Autoimmunity, 10, 100294. https://doi.org/10.1016/j.jtauto.2025.100294
6. Rustgi, S. D., Bijlani, P., & Shah, S. C. (2021). Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management. Therapeutic Advances in Gastroenterology, 14, 17562848211038771. https://doi.org/10.1177/17562848211038771
7. Thain, A., Hart, K., & Ahmadi, K. R. (2025). Addressing the gaps in the vitamin B12 deficiency 2024 NICE guidelines: Highlighting the need for better recognition, diagnosis, and management of pernicious anaemia. European Journal of Clinical Nutrition, 79(7), 607-610. https://doi.org/10.1038/s41430-025-01583-4
8. Sanz-Cuesta, T., Escortell-Mayor, E., Cura-Gonzalez, I., Martin-Fernandez, J., Riesgo-Fuertes, R., Garrido-Elustondo, S., Mariño-Suárez, J. E., Fernández-Pacheco, J. C., Alvarez-Villalba, M., & González-González, R. (2020). Oral versus intramuscular administration of vitamin B12 for vitamin B12 deficiency in primary care: a pragmatic, randomised, non-inferiority clinical trial (OB12). BMJ Open, 10(8), e033687. https://doi.org/10.1136/bmjopen-2019-033687
9. Shah, S. C., Piazuelo, M. B., Kuipers, E. J., & Li, D. (2021). AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology, 161(4), 1325-1332.e7. https://doi.org/10.1053/j.gastro.2021.06.078
10. Lam, J. R., Schneider, J. L., Zhao, W., & Corley, D. A. (2013). Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA, 310(22), 2435-2442. https://doi.org/10.1001/jama.2013.280490

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 6 of The Angry Gut by Dr. Padda and Ami Michelle Grimes. Last reviewed September 2026.